Asset profile
Fruquintinib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Colorectal Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
5 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 4 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fruquintinib: this drug | Approved | Small molecule | VEGFR1/2/3 | ||
| OTX-TKI (axitinib Implant) | Phase 3 | Small molecule | VEGFR1/2/3 | ||
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | ||
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | ||
| PI3Kalpha Precision Therapy | Not yet studied | Small molecule | — | ||
| Simridatug | Not yet studied | Protein / enzyme therapeutic | — |
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(50 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (10)
October 2026 (1)
Phase 1/2Advanced/Metastatic Solid TumorsRecruiting
Est. primary completion 2026-10-31 · NCT05405595 · CT.gov ↗
What to watch
December 2026 (9)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07229872 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CarcinomaNot yet recruiting
Est. primary completion 2026-12-15 · NCT06115733 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-28 · NCT05954429 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06356597 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerRecruiting
Est. primary completion 2026-12-30 · NCT06551207 · CT.gov ↗
What to watch
Phase 1Colon Cancer, Metastatic Colon CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05848739 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05867420 · CT.gov ↗
What to watch
Phase 2Colorectal Neoplasms, RAS, BRAF, Cetuximabβ, FruquintinibRecruiting
Est. primary completion 2026-12-31 · NCT07257653 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05747716 · CT.gov ↗
What to watch
2027 (25)
January 2027 (2)
March 2027 (2)
May 2027 (2)
June 2027 (1)
Phase 2Platinum Resistant Ovarian CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06973421 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07591597 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-06 · NCT07051785 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-28 · NCT07515820 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2027-08 · NCT07483684 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07689292 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07353268 · CT.gov ↗
What to watch
October 2027 (4)
Phase 4Colorectal CancerRecruiting
Est. primary completion 2027-10-04 · NCT06562543 · CT.gov ↗
What to watch
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2027-10-15 · NCT07170982 · CT.gov ↗
What to watch
Phase 2Non-clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-10-22 · NCT05831891 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-10-30 · NCT07261709 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07621159 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Adenocarcinoma MetastaticRecruiting
Est. primary completion 2027-11-30 · NCT07392346 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07384377 · CT.gov ↗
What to watch
December 2027 (5)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-12-01 · NCT07136077 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-12-15 · NCT07622550 · CT.gov ↗
What to watch
Early phase / not applicableGastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT07552402 · CT.gov ↗
What to watch
Phase 2Non-Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT07488533 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT06992258 · CT.gov ↗
What to watch
2028 (10)
February 2028 (1)
Phase 2Metastatic Colorectal Carcinoma (mCRC)Not yet recruiting
Est. primary completion 2028-02-28 · NCT07150403 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1/2Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor, Tislelizumab, GEJ AdenocarcinomaNot yet recruiting
Est. primary completion 2028-03-30 · NCT06871527 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy, Fruquintinib, PD-1Not yet recruiting
Est. primary completion 2028-03-31 · NCT06888037 · CT.gov ↗
What to watch
April 2028 (2)
October 2028 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-10-01 · NCT07724223 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-12 · NCT07042685 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-12-30 · NCT06980532 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07362836 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07502014 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 3Advanced Endometrial CancerRecruiting
Est. primary completion 2029-01-08 · NCT06584032 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 3Metastatic Oesogastric AdenocarcinomaRecruiting
Est. primary completion 2030-11-30 · NCT07270991 · CT.gov ↗
What to watch
2031 (1)
March 2031 (1)
Early phase / not applicableColorectal CancerRecruiting
Est. primary completion 2031-03-01 · NCT07124858 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.